PURPOSE: CD44 is a cell surface glycoprotein involved in cell-cell and cell-substrate interactions, which may be shed or released into circulation by proteolytic enzymatic mechanisms. Alternative splicing of CD44 and aberrant levels of soluble CD44 variants in the serum of cancer patients have been correlated to tumor progression and metastasis in different tumors including breast cancer. In this study we evaluated the clinical value of CD44 serum levels (sCD44) in patients with primary breast cancer. METHODS: Concentrations of soluble isoforms sCD44std, sCD44v5 and sCD44v6 were determined with a sensitive ELISA and normalized against the total protein concentration (TP). Pre-operative serum samples from 82 patients and 67 age-matched healthy blood donors were analyzed. The results were correlated to clinico-pathological parameters (tumor size, grading, lymph node metastasis, etc.). RESULTS: In sera of breast cancer patients, we detected elevated concentrations of sCD44v6 (P = 0.0001) and total protein TP (P = 0.0001) in comparison to healthy controls, whereas overall sCD44 (sCD44std) and sCD44v5 did not differ. Patients with sCD44v6-concentrations above the 75%-percentile showed an increased T stage (2.9 cm vs. 1.8 cm) as well as a higher risk for lymph node metastasis (55% vs. 35%). In breast cancer patients with lymph node metastasis the median value of sCD44v6 was significantly higher (P = 0.025) in comparison to patients without lymph node metastasis and healthy controls. CONCLUSIONS: Our data suggest an upregulated expression of alternatively spliced soluble CD44 isoforms in breast cancer patients. The specific alterations of certain CD44 isoform concentrations (especially sCD44v6) may reflect disturbances of the nuclear splicing machinery in tumor cells. The clinical significance of our findings are underlined by the positive correlation of elevated sCD44v6 concentrations and lymph node metastases (r (s) = 0.25).
PURPOSE:CD44 is a cell surface glycoprotein involved in cell-cell and cell-substrate interactions, which may be shed or released into circulation by proteolytic enzymatic mechanisms. Alternative splicing of CD44 and aberrant levels of soluble CD44 variants in the serum of cancerpatients have been correlated to tumor progression and metastasis in different tumors including breast cancer. In this study we evaluated the clinical value of CD44 serum levels (sCD44) in patients with primary breast cancer. METHODS: Concentrations of soluble isoforms sCD44std, sCD44v5 and sCD44v6 were determined with a sensitive ELISA and normalized against the total protein concentration (TP). Pre-operative serum samples from 82 patients and 67 age-matched healthy blood donors were analyzed. The results were correlated to clinico-pathological parameters (tumor size, grading, lymph node metastasis, etc.). RESULTS: In sera of breast cancerpatients, we detected elevated concentrations of sCD44v6 (P = 0.0001) and total protein TP (P = 0.0001) in comparison to healthy controls, whereas overall sCD44 (sCD44std) and sCD44v5 did not differ. Patients with sCD44v6-concentrations above the 75%-percentile showed an increased T stage (2.9 cm vs. 1.8 cm) as well as a higher risk for lymph node metastasis (55% vs. 35%). In breast cancerpatients with lymph node metastasis the median value of sCD44v6 was significantly higher (P = 0.025) in comparison to patients without lymph node metastasis and healthy controls. CONCLUSIONS: Our data suggest an upregulated expression of alternatively spliced soluble CD44 isoforms in breast cancerpatients. The specific alterations of certain CD44 isoform concentrations (especially sCD44v6) may reflect disturbances of the nuclear splicing machinery in tumor cells. The clinical significance of our findings are underlined by the positive correlation of elevated sCD44v6 concentrations and lymph node metastases (r (s) = 0.25).
Authors: N Guriec; L Marcellin; B Gairard; H Caldéroli; A Wilk; R Renaud; J P Bergerat; F Oberling Journal: Clin Exp Metastasis Date: 1996-10 Impact factor: 5.150
Authors: Aleksandr E Vendrov; Nageswara R Madamanchi; Xi-Lin Niu; Kimberly C Molnar; Mason Runge; Cédric Szyndralewiez; Patrick Page; Marschall S Runge Journal: J Biol Chem Date: 2010-06-17 Impact factor: 5.157
Authors: T Dan; S M Hewitt; N Ohri; D Ly; B P Soule; S L Smith; K Matsuda; C Council; U Shankavaram; M E Lippman; J B Mitchell; K Camphausen; N L Simone Journal: Breast Cancer Res Treat Date: 2013-11-26 Impact factor: 4.872
Authors: Chandramu Chetty; Sravan K Vanamala; Christopher S Gondi; Dzung H Dinh; Meena Gujrati; Jasti S Rao Journal: Cell Signal Date: 2011-10-17 Impact factor: 4.315
Authors: Taavi Päll; Anne Pink; Lagle Kasak; Marina Turkina; Wally Anderson; Andres Valkna; Priit Kogerman Journal: PLoS One Date: 2011-12-21 Impact factor: 3.240